Mankind Pharma Ltd
Mankind Pharma Limited develops, manufactures, and markets pharmaceutical formulations and consumer healthcare products in India and internationally. The company develops pharmaceuticals for acute and chronic therapeutics in the areas of anti-infective, cardiovascular, gastrointestinal, gynaecology, anti-diabetic, dermatology, pain/analgesics, neuro/CNS, vitamins/minerals/nutrients, respiratory d… Read more
Mankind Pharma Ltd (MANKIND) - Total Liabilities
Latest total liabilities as of September 2025: ₹132.85 Billion INR
Based on the latest financial reports, Mankind Pharma Ltd (MANKIND) has total liabilities worth ₹132.85 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Mankind Pharma Ltd - Total Liabilities Trend (2019–2025)
This chart illustrates how Mankind Pharma Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Mankind Pharma Ltd Competitors by Total Liabilities
The table below lists competitors of Mankind Pharma Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Steel Authority of India Limited
NSE:SAIL
|
India | ₹758.85 Billion |
|
China Nuclear Engineering Co
SHG:601611
|
China | CN¥210.05 Billion |
|
Biocon Limited
NSE:BIOCON
|
India | ₹295.40 Billion |
|
Stella-Jones Inc
PINK:STLJF
|
USA | $1.98 Billion |
|
China Zhenhua Group Science & Technology Co Ltd
SHE:000733
|
China | CN¥3.37 Billion |
|
Silicon Motion Technology Corporation
F:S9M
|
Germany | €303.22 Million |
|
Tav Havalimanlari Holding AS
PINK:TAVHY
|
USA | $3.55 Billion |
Liability Composition Analysis (2019–2025)
This chart breaks down Mankind Pharma Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.46 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Mankind Pharma Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Mankind Pharma Ltd (2019–2025)
The table below shows the annual total liabilities of Mankind Pharma Ltd from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹131.91 Billion | +452.53% |
| 2024-03-31 | ₹23.87 Billion | +15.52% |
| 2023-03-31 | ₹20.67 Billion | -27.01% |
| 2022-03-31 | ₹28.31 Billion | +87.54% |
| 2021-03-31 | ₹15.10 Billion | +7.71% |
| 2020-03-31 | ₹14.02 Billion | +23.96% |
| 2019-03-31 | ₹11.31 Billion | -- |